Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
1,079 INR | -0.09% | +5.16% | +26.39% |
Apr. 25 | Glenmark Lifesciences' Net Profit Slides in Fiscal Q4 | MT |
Apr. 01 | Glenmark Pharmaceuticals Limited Announces Board Changes | CI |
Sales 2024 * | 121B 1.46B | Sales 2025 * | 140B 1.68B | Capitalization | 305B 3.66B |
---|---|---|---|---|---|
Net income 2024 * | 33.36B 400M | Net income 2025 * | 11.13B 134M | EV / Sales 2024 * | 2.67 x |
Net Debt 2024 * | 19.84B 238M | Net cash position 2025 * | 3.08B 36.96M | EV / Sales 2025 * | 2.15 x |
P/E ratio 2024 * |
42.6
x | P/E ratio 2025 * |
25.1
x | Employees | 15,556 |
Yield 2024 * |
0.21% | Yield 2025 * |
0.26% | Free-Float | 49.03% |
Latest transcript on Glenmark Pharmaceuticals Limited
1 day | -0.43% | ||
1 week | +4.80% | ||
Current month | +12.23% | ||
1 month | +12.37% | ||
3 months | +19.54% | ||
6 months | +43.59% | ||
Current year | +25.96% |
Managers | Title | Age | Since |
---|---|---|---|
Founder | - | - | |
Chief Executive Officer | 54 | 98-10-11 | |
Ulhas Dhuppad
PSD | President | - | - |
Members of the board | Title | Age | Since |
---|---|---|---|
Director/Board Member | 59 | 20-08-13 | |
Cherylann Pinto
BRD | Director/Board Member | 56 | 99-10-05 |
Chief Executive Officer | 54 | 98-10-11 |
Name | Weight | AuM | 1st Jan change | Investor Rating |
---|---|---|---|---|
0.02% | 4 M€ | -4.41% | - | |
0.01% | 117 M€ | +0.16% | - |
Date | Price | Change | Volume |
---|---|---|---|
24-04-26 | 1,079 | -0.09% | 475 440 |
24-04-25 | 1,080 | +0.87% | 1,101,089 |
24-04-24 | 1,071 | +3.52% | 657,378 |
24-04-23 | 1,034 | -0.47% | 1,223,564 |
24-04-22 | 1,039 | +1.26% | 260,452 |
Delayed Quote NSE India S.E., April 26, 2024 at 03:35 am EDT
More quotesEPS Revisions
Quarterly revenue - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
+25.96% | 3.66B | |
+20.44% | 21.89B | |
+13.16% | 14.45B | |
+13.09% | 13.63B | |
+37.77% | 11.49B | |
-8.59% | 6.85B | |
-0.05% | 6.79B | |
-8.87% | 5.73B | |
+6.35% | 5.06B | |
-5.36% | 4.66B |
- Stock Market
- Equities
- GLENMARK Stock